Quorum Innovations


Quorum Innovations is a biopharmaceutical company focused on discovering and developing human microbiome therapeutics. The company aims to become a leader in the emerging field of microbiome therapeutics, leveraging its proprietary drug discovery platform, MiNE™, to identify biotherapeutic candidates that stimulate the innate immune response and restore normal microbiome ecology.

Quorum Innovations Logo

Quorum Innovations


What We Do

A Probiotic Essence for the Skin, part of Quorum Innovations' skin care line that utilizes ProBiomic™ technology to promote skin health.


Regenerative Medicine


Key People

Nicholas T. Monsul, M.D., F.A.C.S.

Co-Founder and Chairman

LinkedIn

Eva A. Berkes, M.D.

Co-Founder and Chief Scientific Officer

LinkedIn

John J. Cunningham, Jr., Esq.

Consulting General Counsel

LinkedIn

Frederick T. Boehm, J.D.

Vice President, Patent and Legal Affairs

LinkedIn

News & Updates

Dr. Nicholas Monsul will deliver a key address at the Annual Microbiome Summit in Vienna, Austria, discussing the capabilities to modulate the skin microbiota.

Quorum Innovations announced a major advancement in improving immune responses and skin/mucosal barrier by modulating the human microbiome.

Quorum Innovations is included in SVB Analytics - Emerging Healthcare: / 2017.

Quorum Innovations announced a major milestone that includes a drug discovery platform to advance the introduction of new treatments for skin, GI, inflammatory and metabolic conditions utilizing human microbiome therapeutics.

Quorum Innovations has successfully isolated LfQi6 from the human host, demonstrating strong biofilm formations and novel bimodal biofilm modulation.

U.S. Patent 9,504,739

Method of Identifying Biologically Active Compounds from Microbial Biofilm. (Issued 11/2016; Priority 3/2011)